Since the original descriptions of putrefaction by Hippocrates, sepsis has been recognized as a major cause of human suffering and mortality. Despite major advances made in understanding the systemic inflammatory response to infection, clinical trials of sepsis therapeutics have been repeatedly disappointing. These failure highlight the need for new, multidisciplinary perspectives into the onset, progression, and resolution of septic organ injury. The endothelial glycocalyx is a layer of glycosaminoglycans and associated proteoglycans lining the vascular surface. In vivo, the glycocalyx forms a substantial endothelial surface layer (ESL) that influences inflammation, endothelial permeability, and vascular tone-biologic processes highly relevant to sepsis pathophysiology. We have recently identified that the pulmonary ESL, by regulating exposure of endothelial surface adhesion molecules, serves a gatekeeping function controlling neutrophil transit into the lung. In response to an infectious stimulus, activated endothelial cells cleave the pulmonary ESL, allowing neutrophil adhesion and subsequent extravasation. Teleologically, this gatekeeping function would additionally require precise cellular control of ESL reconstitution, thereby limiting the magnitude of pulmonary inflammation. These processes of ESL repair, despite therapeutic relevance to patients with sepsis, have been unexplored. We hypothesize that a degraded pulmonary ESL is rapidly reconstituted in otherwise-healthy mice, allowing for maintenance of pulmonary vascular homeostasis. During sepsis, ESL reconstitution is delayed, contributing to the excessive pulmonary inflammation and edema characteristic of septic lung injury. Using state-of-the-art pulmonary intravital microscopy (E. Schmidt, Pulmonary/Critical Care, University of Colorado) and glycomic (R. Linhardt, Chemistry, Rensselaer Polytechnic Institute) approaches, we propose to (1) determine the mechanisms underlying pulmonary ESL reconstitution, (2) identify how these mechanisms are suppressed during sepsis, and (3) therapeutically manipulate these mechanisms to accelerate ESL reconstitution and attenuate septic lung injury. These multidisciplinary investigations, representing a highly novel collaboration within the field of sepsis, will be complemented by animal models of septic lung injury as well as analyses of biologic samples obtained from humans with severe sepsis. In summary, this proposal offers a new, multidisciplinary perspective on sepsis: that ESL integrity is a critical determinant of the onset and progression of septic organ injury. Investigating processes of ESL reconstitution may therefore identify novel therapeutic targets in a critical illness that, despite millennia of study, still lacks a clinically-efficacious, pathophysiology-targeted treatment.

Public Health Relevance

Sepsis is a common, severe condition caused by the body's response to an overwhelming infection. Sepsis can cause harm to people by damaging an important layer of sugars that lines blood vessels in the lungs. We are studying how this damaged layer of sugars can be repaired, so that we can find a new, effective treatment for sepsis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL125371-03
Application #
9066215
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Sarkar, Rita
Project Start
2014-09-15
Project End
2019-05-31
Budget Start
2016-06-01
Budget End
2017-05-31
Support Year
3
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Haeger, Sarah M; Liu, Xinyue; Han, Xiaorui et al. (2018) Epithelial Heparan Sulfate Contributes to Alveolar Barrier Function and Is Shed during Lung Injury. Am J Respir Cell Mol Biol 59:363-374
Middleton, Dustin R; Zhang, Xing; Wantuch, Paeton L et al. (2018) Identification and characterization of the Streptococcus pneumoniae type 3 capsule-specific glycoside hydrolase of Paenibacillus species 32352. Glycobiology 28:90-99
Kizer, Megan; Li, Peiqin; Cress, Brady F et al. (2018) RNA Aptamers with Specificity for Heparosan and Chondroitin Glycosaminoglycans. ACS Omega 3:13667-13675
Oshima, Kaori; Haeger, Sarah M; Hippensteel, Joseph A et al. (2018) More than a biomarker: the systemic consequences of heparan sulfate fragments released during endothelial surface layer degradation (2017 Grover Conference Series). Pulm Circ 8:2045893217745786
Zhao, Jing; Kong, Yan; Zhang, Fuming et al. (2018) Impact of Temperature on Heparin and Protein Interactions. Biochem Physiol 7:
Peng, Yanfei; Yu, Yanlei; Lin, Lei et al. (2018) Glycosaminoglycans from bovine eye vitreous humour and interaction with collagen type II. Glycoconj J 35:119-128
Xiao, Yiming; Li, Miaomiao; Larocque, Rinzhi et al. (2018) Dimerization interface of osteoprotegerin revealed by hydrogen-deuterium exchange mass spectrometry. J Biol Chem 293:17523-17535
Lin, Yi-Pin; Li, Lingyun; Zhang, Fuming et al. (2017) Borrelia burgdorferi glycosaminoglycan-binding proteins: a potential target for new therapeutics against Lyme disease. Microbiology 163:1759-1766
Yang, Yimu; Haeger, Sarah M; Suflita, Matthew A et al. (2017) Fibroblast Growth Factor Signaling Mediates Pulmonary Endothelial Glycocalyx Reconstitution. Am J Respir Cell Mol Biol 56:727-737
Xu, Yongmei; Chandarajoti, Kasemsiri; Zhang, Xing et al. (2017) Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins. Sci Transl Med 9:

Showing the most recent 10 out of 28 publications